CYTOF · Altamira Therapeutics Ltd.
Market Cap
$405,798
Shares
5.72M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
379
-99.9%
FY2023
Gross Margin
-372.44%
+3034.9pp
FY2022
Diluted EPS
-$2.99
+65.9%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| CHF | — | 379 | 305.62K | 63.88K |
| CHF | — | 33.97K | 1.44M | 2.24M |
| CHF | — | — | -1.14M | -2.18M |
| CHF | — | — | 2.38M | 1.5M |
| USD/shares | -$2.99 | -$8.77 | -$610.03 | — |
| USD/shares | -$2.99 | -$8.77 | -$610.03 | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.